Scholar Rock (SRRK) Stock Price, News & Analysis

Company Overview

Scholar Rock Holdings, Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary Protein Expression Control (PEC) platform to discover and develop innovative therapies that modulate key growth factors. By targeting critical nodes in the transforming growth factor-beta (TGF-β) superfamily, Scholar Rock aims to restore functional muscle growth, enhance tissue repair and overcome immune suppression in various diseases with high unmet medical needs.

The company’s lead therapeutic candidate, apitegromab (SRK-015), is an investigational monoclonal antibody designed to inhibit the activation of myostatin, a negative regulator of muscle mass. Apitegromab is being evaluated in spinal muscular atrophy (SMA) patients to improve motor function and muscle strength across multiple age groups and disease severities. In parallel, Scholar Rock is advancing SRK-181, a highly selective activin A inhibitor, which is under investigation for its potential to augment immune checkpoint inhibitors in pancreatic ductal adenocarcinoma and other solid tumors where immune evasion is driven by activin A signaling. Additional pipeline programs are exploring modulation of growth factors in fibrotic, neuromuscular and oncology indications.

Founded in 2010 and headquartered in Cambridge, Massachusetts, Scholar Rock has built a team of scientists, clinicians and industry veterans dedicated to translating its mechanistic insights into differentiated therapies. The company conducts its clinical trials across North America and Europe, collaborating with leading academic centers and clinical research organizations to advance its candidates through early- and late-stage studies. Strategic partnerships and collaborations have been established to enhance development capabilities and broaden global access to potential future therapies.

Under the leadership of President and Chief Executive Officer Jason Rhodes, Scholar Rock continues to refine its PEC platform and expand its pipeline. Guided by a board comprised of accomplished biopharma executives and scientific advisors, the company remains focused on delivering first-in-class or best-in-class therapeutics. With a commitment to addressing severe and underserved conditions, Scholar Rock combines deep biology expertise with disciplined clinical development to bring novel growth factor modulators to patients worldwide.

Key Stats

• Today's Range: $34.89 to $35.99
• 50-Day Range: $28.86 to $36.32
• 52-Week Range: $6.76 to $46.98
• Volume: 481,993 shs
• Average Volume: 1.29 million shs
• Market Capitalization: $3.36 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $42.67
• Consensus Rating: Buy

Scholar Rock Stock Analysis - MarketRank™

Scholar Rock scored higher than 67% of companies evaluated by MarketBeat, and ranked 331st out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.6 / 5
• Analyst Rating: Buy

Consensus Rating

Scholar Rock has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Scholar Rock has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Scholar Rock are expected to grow in the coming year, from ($2.42) to ($2.12) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Scholar Rock is -13.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Scholar Rock is -13.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Scholar Rock has a P/B Ratio of 8.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.14% of the float of Scholar Rock has been sold short.

Short Interest Ratio / Days to Cover

Scholar Rock has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Scholar Rock has recently increased by 4.92%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Scholar Rock does not currently pay a dividend.

Dividend Growth

Scholar Rock does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.09

Percentage of Shares Shorted

18.14% of the float of Scholar Rock has been sold short.

Short Interest Ratio / Days to Cover

Scholar Rock has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Scholar Rock has recently increased by 4.92%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Scholar Rock this week, compared to 7 articles on an average week.

Search Interest

7 people have searched for SRRK on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.

MarketBeat Follows

5 people have added Scholar Rock to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Scholar Rock insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,991,465.00 in company stock.

Percentage Held by Insiders

13.30% of the stock of Scholar Rock is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

91.08% of the stock of Scholar Rock is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SRRK Stock Analysis - Frequently Asked Questions

How have SRRK shares performed this year?

Scholar Rock's stock was trading at $43.22 on January 1st, 2025. Since then, SRRK shares have decreased by 18.2% and is now trading at $35.35.

How were Scholar Rock's earnings last quarter?

Scholar Rock Holding Corporation (NASDAQ:SRRK) posted its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.63) by $0.04.
Read the conference call transcript.

When did Scholar Rock IPO?

Scholar Rock (SRRK) raised $76 million in an initial public offering on Thursday, May 24th 2018. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

How do I buy shares of Scholar Rock?

Shares of SRRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Scholar Rock own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Scholar Rock investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA), First Solar (FSLR) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/05/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SRRK
• CIK: 1727196
• Web: www.scholarrock.com
• Phone: (857) 259-3860
• Fax: 866-493-4935
• Employees: 140
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $42.67
• High Stock Price Target: $50.00
• Low Stock Price Target: $31.00
• Potential Upside/Downside: +20.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.14
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$246.29 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -118.22%
• Return on Assets: -82.01%

Debt

• Debt-to-Equity Ratio: 0.16
• Current Ratio: 10.25
• Quick Ratio: 10.25

Sales & Book Value

• Annual Sales: $33.19 million
• Price / Sales: 101.13
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.94 per share
• Price / Book: 8.97

Miscellaneous

• Outstanding Shares: 94,950,000
• Free Float: 82,318,000
• Market Cap: $3.36 billion
• Optionable: Optionable
• Beta: 0.33